Blog
RSS FeedPosted by Michael Wonder on 03 May 2022
Unwanted advice? Frequency, characteristics and outcomes of negative advisory committee votes for FDA approved drugs
2 May 2022 - Substantial controversy arose in 2021 when the FDA approved the Alzheimer’s disease drug aducanumab (Aduhelm) under its ...